Market Overview

Catalent Analyst Cites Valuation Concerns In Downgrade

Catalent Analyst Cites Valuation Concerns In Downgrade

KeyBanc Capital Market's bull case for Catalent Inc (NYSE: CTLT) has come to an end.

The company has taken the necessary steps to gain exposure to the high-growth biologics and gene therapy space, according to the sell-side firm. 

The Analyst

Donald Hooker downgraded Catalent from Overweight to Sector Weight.

The Thesis

Catalent reported in-line fourth-quarter results that were highlighted by a 4% organic revenue growth and "stable" EBITDA, Hooker said in a Tuesday downgrade note. (See his track record here.) 

The company's acquisitions are showing signs of success, including Paragon Bioservices, which contributed $29 million in revenue, while Juniper Pharmaceuticals added another $15 million, the analyst said. 

The company ended the fiscal year on an encouraging note, with $646 million of development revenue at an estimated mid-to-high-single-digit organic growth rate, he said.

Catalent also introduced 193 new products in fiscal 2019 that accounted for $103 million of revenue, Hooker said. 

The recent momentum should continue, as Catalent is expected to show 8% organic revenue growth rate in fiscal 2020 and the year after, the analyst said.

The Paragon Bioservices business should increase its contribution and is modeled to generate around $270 million in revenue and around $82 million of EBITDA in fiscal 2020, with 30% or more revenue growth afterwards, he said. 

Company-wide EBITDA is now modeled to grow at 10% over the next few years, Hooker said.

Yet Catalent's free cash flow is likely to be limited to 20% to 30% of EBITDA due to heavy capital spending, the analyst said. The company's "flexibility" could be impacted by its high debt ratio of around 4.2 times EBITDA, he said. 

KeyBanc's bullish stance on Catalent datesto March 2018, but shares are now trading near all-time highs in terms of a dollar amount and valuation at 15 times 2020 EBITDA, the sell-side firm said. 

Price Action

Catalent shares were down 0.28% at $52.68 at the time of publication Wednesday. 

Related Links:

'Uniquely Positioned' Catalent Notches KeyBanc Upgrade

Raymond James Projects 'Rising Momentum' At Catalent Driven By Biologics Expansion

Latest Ratings for CTLT

Dec 2020KeyBancUpgradesSector WeightOverweight
Nov 2020Morgan StanleyMaintainsOverweight
Sep 2020Morgan StanleyMaintainsOverweight

View More Analyst Ratings for CTLT
View the Latest Analyst Ratings


Related Articles (CTLT)

View Comments and Join the Discussion!

Posted-In: Biologics Donald Hooker gene therapyAnalyst Color Biotech Downgrades Analyst Ratings General Best of Benzinga

Latest Ratings

EYPTCantor FitzgeraldInitiates Coverage On22.0
TXNDeutsche BankMaintains170.0
BYDDeutsche BankMaintains56.0
MELIDeutsche BankMaintains2,200.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at